Cure My Disease

Don't miss your cure!

 Log in / Sign up

New tracer maps brain inflammation in healthy people

NCT ID NCT06398392

Knowledge-focused Sponsor: Prof. Daniele Zullino Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This completed study tested a radioactive tracer called [18F]PBR111 in 6 healthy adults (3 men, 3 women) to see how it spreads in the body and how much radiation it gives off. The tracer is designed to attach to a protein that appears during brain inflammation, which could help doctors spot conditions like Alzheimer's or multiple sclerosis. The goal was to measure radiation dosimetry and biodistribution using PET/CT scans over 120 minutes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
[18F]PBR111 (radioactive tracer)
What this could lead to
If successful, this could help develop better PET scans to detect brain inflammation in diseases like Alzheimer's or multiple sclerosis.
What could go wrong
This is a very small, early study in just 6 healthy people. It only measures radiation exposure, not treatment effects, so it won't directly help patients yet.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

6 people

The number who actually took part.

Started

Jun 2024

Finished

Jul 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aged ≥18 (3 male and 3 female participants) * Fluent in French and able and willing to provide written informed consent. Exclusion Criteria: * Homozygosity for the rs6971 polymorphism on TSPO that results in low-affinity binding. This criterion is added because this polymorphism alters significantly the ability of the radiotracer \[18F\]PBR111 to bind to TSPO, hence precluding quantification. * Absence of a stable contraceptive regimen (specifically, intrauterine contraceptive device or contraceptive treatment per os). Only women with stable contraception will be added to eliminate the risk of exposure of pregnant women and their foetus to radioactivity. * Presence of any significant history or current diagnosis of chronic disease or syndrome (including neurological, psychiatric, cardiovascular, oncological, metabolic, rheumatological conditions). * One or more episode(s) of acute infectious or allergic reaction in the last month before inclusion and during the study period. Again, we cannot exclude that such conditions might produce immune alterations in the brain, thus confounding the results of TSPO quantification with \[18F\]PBR111. * Presence of clinically relevant laboratory abnormalities in the haematological and biochemical blood tests, as defined as laboratory values that require clinical workup and/or treatment (e.g. anaemia, hyperglycaemia, electrolyte imbalances) * A body mass index \<20 or \>30 (this criterion is necessary because TSPO has been shown to be variable with respect to body mass index (113-115)). * Exposure to research related radiation in the past five years that, when combined with this study, would place subjects above the allowable limits. * Conditions precluding entry into the scanners (e.g. claustrophobia).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Dosimetry are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Dosimetry Healthy

Contacts and locations

Locations

  • Geneva University Hospital

    Geneva, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.